Table 2.
Baseline characteristics of the enrolled patients in the included studies
| Study ID | Study arms | Sample | Age, years, M ± SD | BMI, kg/m2, M ± SD | Nulliparous | Median gestation at entry, wk (IQR) | Race, white/black/others |
|---|---|---|---|---|---|---|---|
| Cairns et al. 2018 [28] | HBPM | 45 | 31.7 ± 5.3 | 29 ± 7.5 | 32 (71%) | 35.9 (31.9–37.7) | 41/4 |
| Control | 46 | 31.7 ± 5.3 | 28 ± 8.3 | 31 (67%) | 34.7 (31.7–36.9) | 43/3 | |
| Chappell et al. 2022 [36] | Chronic Hypertension (HBPM) | 233 | 36 ± 5.4 | 30.7 (26.7–34.7)a | 85 (36.5%) | 18.6 (15.3–23.3) | 115/70/38 |
| Chronic Hypertension (Control) | 221 | 35.5 ± 5.8 | 30.5 (26.3–35.8)a | 77 (34.8%) | 18.3 (15.4–23.3) | 109/71/41 | |
| Gestational Hypertension (HBPM) | 197 | 33.5 ± 6.1 | 29.4 (24.8–35.1)a | 103 (52.3%) | 34.3 (29.7–35.9) | 141/17/39 | |
| Gestational Hypertension (Control) | 199 | 33.6 ± 5.6 | 28.5 (25–35.4)a | 101 (50.8%) | 33.9 (30.3–36.1) | 137/22/40 | |
| Denolle et al. 2008 [35] | HBPM | 24 | 27 ± 3 | - | 39 (82%) | 29 ± 5$ | - |
| Control | 24 | - | - | ||||
| Fukushima et al. 2002 [30] | HBPM | 19 | 29.7 ± 7.6 | - | 71 (36%) | 19.6 ± 9.8$ | - |
| Control | 180 | - | 27.5 ± 9.3$ | - | |||
| Hirshberg et al. 2018 [27] | HBPM | 103 | 28 ± 6 | 30.1 (24.3–33.8)a | 61 (59.2%) | 38 (36–39) | 28/68/7 |
| Control | 103 | 28 ± 5 | 31.0 (25.1–38.3)a | 52 (50.5%) | 38 (36–39) | 25/73/5 | |
| Holm et al. 2019 | HBPM | 80 | - | - | - | - | - |
| Control | - | - | - | - | - | ||
| Hoppe et al. 2020 [29] | HBPM | 214 | - | - | - | - | - |
| Control | 214 | - | - | - | - | - | |
| Kalafat et al. 2019 [31] | HBPM | 80 | 34.0 (30.0–37.0)a | 26.4 (23.6–30.0)a | 59 (73.7%) | 34.0 (28.2–36.3) | - |
| Control | 63 | 31.0 (28.0- 33.5)a | 27.1 (24.2–30.3)a | 51 (80.9%) | 36.0 (33.0–37.3) | - | |
| Lanssens et al. 2018–1 [32] | HBPM | 86 | 30.97 ± 5.61 | 26.79 ± 5.36 | - | 10.51 ± 6.11$ | - |
| Control | 215 | 30.53 ± 5.17 | 28.38 ± 6.67 | - | 10.60 ± 5.52$ | - | |
| Kitt et al. 2021 [23] | HBPM | 30 | 35.2 ± 5.3 | 28.5 (25.6–33.3)a | 0 | - | - |
| Control | 31 | 34.1 ± 5.3 | 27.7 (23.9–31.4)a | 0 | - | - | |
| Pealing et al. 2019-Chronic Hypertension [25] | HBPM | 55 | 35.9 ± 5.6 | 31 ± 7 | 17 (31%) | 16.6 (12.9–20.1) | 27/21/7 |
| Control | 31 | 31.7 ± 5.3 | 31.9 ± 7 | 9 (29%) | 14.9 (13.0–20.0) | 21/8/3 | |
| Pealing et al. 2019-Gestational Hypertension [25] | HBPM | 49 | 33.4 ± 5.9 | 29.5 ± 7.1 | 20 (41%) | 35.0 (32.4–36.1) | 37/11/1 |
| Control | 23 | 34.2 ± 5.1 | 27.6 ± 6.4 | 14 (61%) | 34.7 (32.1–36.4) | 18/4/1 | |
| Perry et al. 2018 [13] | HBPM | 108 | 32.5 (29.0–37.8)a | 27.7 (23.8–33.2)a | 61 (56.5%) | 30.0 (22.0–35.0) | - |
| Control | 58 | 32.0 (28.0–35.3)a | 27.9 (24.9–31.2)a | 32 (55.2%) | 33.6 (28.2–36.1) | - | |
| Rayburn et al. 1985 [33] | HBPM | 33 | 31 ± 3 | 11 (33.3%) | - | 35 ± 3$ | - |
| Control | 34 | 30 ± 4 | 14 (41.2%) | - | 36 ± 3$ | - | |
| Rhodes et al. 2017 [34] | HBPM | 51 | 26.2 ± 4.3 | 32 (62%) | - | - | - |
| Control | 49 | 27.3 ± 6 | 32 (65%) | - | - | - | |
| Tucker et al. 2022 [24] | HBPM | 1220 | 32.8 ± 5.7 | 26.5 (22.7–32.1)a | 745 (61.1%) | - | 887/88/236 |
| Control | 1217 | 33 ± 5.6 | 26.1 (22.6–32.4)a | 742 (61.0%) | - | 914/99/204 |
Abbreviations: HBPM Home blood pressure management, BMI Body mass index. adata represented as median and IQR, $: data represented as M ± SD